Median Technologies is advancing with its eyonis™LCS AI-powered software for early detection of lung cancer.
Vienna, February 26 – March 2, 2025—The European Congress of Radiology (ECR) 2025 brings together the global radiology community under the theme “Planet Radiology” to explore the latest innovations in diagnostic imaging, including the transformative role of artificial intelligence (AI) in cancer detection. A prime example is the eyonis™ LCS, an AI-driven medical device by Median Technologies, designed to enhance lung cancer screening.
Median Technologies is exhibiting the latest advancements of eyonis™, their next-generation end-to-end AI/ML tech-based CADe CADx Software as Medical Devices (SaMDs) with unprecedented performance.
eyonis™ LCS is a cutting-edge AI-powered software developed to assist radiologists in the early detection of lung cancer. The software analyzes low-dose computed tomography (LDCT) scans, a key diagnostic tool for early-stage lung cancer, and supports radiologists in identifying suspicious nodules.
“We die more from cancer than we did 30 years ago with a 25% increase,” Frederik Brag, CEO and Founder of Median Technologies stated in a pre-event webinar. “Early detection greatly impacts survival rates. If you detect it in stage one, you have a much higher risk of saving your patient.”
Early detection is critical for improving patient outcomes since lung cancer is often asymptomatic in its early stages. By identifying tumors when they are small and treatable, eyonis™ LCS could significantly reduce lung cancer mortality.
Clinical Milestones and Trial Successes
eyonis™ LCS has reached important milestones, having been rigorously tested in two pivotal clinical trials, REALITY (NCT06576232) and RELIVE (NCT06751576). Both studies evaluated the effectiveness of the software in detecting early-stage lung cancer using LDCT imaging. The trials adhered to protocols developed in consultation with the U.S. Food and Drug Administration (FDA) to ensure compliance with regulatory standards.
In the RELIVE trial, the software achieved statistically significant results, demonstrating a meaningful improvement in diagnostic accuracy when used alongside radiologist assessments. In particular, eyonis™ LCS showed an improvement in detecting and characterizing lung nodules, reducing false positives, and helping prevent unnecessary medical interventions. These results were measured against a control group in which radiologists assessed the scans without AI assistance.
The next step for eyonis™ LCS is regulatory approval. Median Technologies is preparing submissions for the FDA’s 510(k) clearance and the European CE mark, both expected in the second quarter of 2025. Once these approvals are obtained, the company plans to launch the software commercially later in the year. These approvals will enable eyonis™ LCS to be deployed in lung cancer screening programs across the U.S. and Europe, marking a significant step forward in AI-driven healthcare.
The company’s Lead Scientist, Hubert Beaumont, delivered a scientific presentation during ECR entitled “Discord Dilemmas in Lung Cancer Clinical Trials: Navigating Reader Variability in Response Assessment”. This session focused on the challenges posed by variability in radiologist interpretations during clinical trials and how AI can help standardize and improve response assessments.
You can access an on-demand replay here.
The Future of AI in Lung Cancer Screening
Lung cancer remains one of the most deadly forms of cancer worldwide, and the need for innovative screening tools is critical. AI-based solutions like eyonis™ LCS represent a promising advancement in addressing this need. By reducing the chances of human error, streamlining the diagnostic process, and improving the accuracy of nodule detection, eyonis™ LCS could play a pivotal role in lung cancer management.
Dr. Valérie Bourdès, VP of Clinical and Medical Affairs at Median Technologies, had the opportunity to express the benefits and explain how it works during an AI Lightning Talk. Attendees gained insights into how eyonis™ LCS integrates AI into radiological workflows to improve diagnostic accuracy and efficiency, particularly in lung cancer screening.
The use of AI in radiology extends beyond lung cancer detection. As AI algorithms continue to evolve, they are being integrated into more aspects of medical imaging, including risk stratification, image analysis, and even treatment planning. This growing role of AI in healthcare is helping to drive more personalized, accurate, and timely medical interventions.
As ECR 2025 unfolds, Median Technologies stands at the forefront of AI innovation in lung cancer screening. With its eyonis™ LCS system poised to enter the global market, the company is helping radiologists detect lung cancer earlier and more accurately.
For medical professionals attending the congress, this represents an opportunity to engage with cutting-edge AI tools that could soon be part of everyday clinical practice. Through their presentations and discussions at ECR, Median Technologies continues to lead the conversation on the future of lung cancer screening and diagnostic imaging.
